Saturday 10 October 2026 Export all PFE data to Excel Powerpack

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

28.28 0.46 +1.65%

Follow PFE

Alert me

Market cap: $158.6B
P/E: 37.2×
Fwd P/E: 12.2×
Dividend yield: 6.08%
F-score: 6/9
Altman Z: 2.03
Beneish M: −2.52
Dividend safety: 28/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total buys 2.96

Total sells 0.13

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	3	—	—
Sell	—	—	—	—	—	—	—	1	—	1	—	—

Insider Ownership 0.16%

Capital & Financial Ratios $m

Market Cap 158,560.00

Revenue 63,696.00

Net Income 4,369.00

Free Cash Flow 10,985.00

Net Debt 51,495.00

Current Ratio 1.27

Debt/Equity 0.74

P/E ratio 37.21

Fwd P/E 12.20

P/S ratio 2.53

P/B ratio 1.89

Past 5Y EPS Growth (4.48%)

This Y EPS Growth (7.79%)

Next Y EPS Growth (2.30%)

Next Y revenue growth (0.55%)

Next 5Y EPS Growth (8.25%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 96.17%

10-year low 10-year high

P/S against its own 10 years 25.41%

10-year low 10-year high

P/B against its own 10 years 26.44%

10-year low 10-year high

EV/Sales against its own 10 years 31.98%

10-year low 10-year high

EV/FCF against its own 10 years 71.45%

10-year low 10-year high

Dividends

Payout Ratio 2.26

Annual Dividend Rate 1.72

Annual Dividend Yield 6.08%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	1.72	0.43 0.43 0.43
2025	1.72	0.43 0.43 0.43 0.43
2024	1.68	0.42 0.42 0.42 0.42
2023	1.64	0.41 0.41 0.41 0.41
2022	1.60	0.40 0.40 0.40 0.40
2021	1.56	0.39 0.39 0.39 0.39
2020	1.52	0.38 0.38 0.38 0.38
2019	1.44	0.36 0.36 0.36 0.36
2018	1.36	0.34 0.34 0.34 0.34
2017	1.28	0.32 0.32 0.32 0.32
2016	1.20	0.30 0.30 0.30 0.30

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	12,690	20,477	13,596	11,699
Receivables	11,566	11,463	11,874	12,490
Inventory	10,189	10,851	10,654	9,945
Other	8,889	7,567	6,775	7,224
	43,333	50,358	42,898	41,358

	2023	2024	2025	Q'26
Payables	6,710	5,633	5,240	4,581
ST’ Debt	10,350	6,946	3,154	2,699
Other	20,537	19,720	18,648	19,709
	47,794	42,995	36,984	32,646

Compound Annual Growth %

	10y	5y	3y
Sales	2.51%	8.48%	(14.80%)
Cash Flow	(2.25%)	(4.07%)	(26.33%)
Earnings	1.11%	(3.23%)	(37.20%)
Book Value	2.93%	6.45%	(3.28%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	14,451	15,034	—	—	—
’25	13,715	14,653	16,654	17,557	62,579
’24	14,879	13,283	17,702	17,763	63,627
’23	18,486	13,007	13,491	14,569	59,553
’22	25,661	27,742	22,638	25,134	101,175
’21	14,516	18,899	24,035	23,838	81,288
’20	10,083	9,864	10,277	11,427	41,651

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2,615	835	—	—	—
’25	2,335	(582)	4,603	5,348	11,704
’24	1,090	(1,781)	6,714	6,721	12,744
’23	1,212	(1,208)	3,456	5,240	8,700
’22	6,541	8,170	5,974	8,582	29,267
’21	4,538	11,299	10,829	5,914	32,580
’20	3,133	3,555	2,090	5,625	14,403

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2,179	302	—	—	—
’25	1,771	(1,200)	4,001	4,503	9,075
’24	386	(2,418)	6,063	5,804	9,835
’23	73	(2,122)	2,646	4,196	4,793
’22	5,898	7,419	5,133	7,581	26,031
’21	3,984	10,762	10,211	4,912	29,869
’20	2,684	3,098	1,583	4,273	11,638

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.47	(0.04)	—	—	—
’25	0.52	0.51	0.62	(0.29)	1.36
’24	0.55	0.01	0.78	0.07	1.41
’23	0.97	0.41	(0.42)	(0.60)	0.37
’22	1.37	1.73	1.51	0.87	5.47
’21	0.86	0.98	1.42	0.59	3.85
’20	0.61	0.61	0.39	0.10	1.71

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	26.80	29.32	31.50	32.23	26.45	33.36	41.45	25.76	24.48	20.92	Analyst estimates 2026–2028 Powerpack
	High	35.47	35.44	44.09	42.28	43.08	61.71	58.55	51.60	31.54	27.69
People
People	Employees	96,500	90,200	92,400	88,300	78,500	79,000	83,000	88,000	81,000	75,000
	Revenue/emp, $m	0.55	0.58	0.44	0.46	0.53	1.03	1.22	0.68	0.79	0.83
Income, $m
Income, $m	Revenue	52,824	52,546	40,825	40,905	41,651	81,288	101,175	59,553	63,627	62,579
	Gross margin, %	76.67	78.63	77.99	80.31	79.63	62.08	66.05	58.10	71.94	74.33
	EBT	8,351	12,305	3,594	11,321	7,036	24,311	34,729	1,058	8,023	7,520
	EBT margin, %	15.81	23.42	8.80	27.68	16.89	29.91	34.33	1.78	12.61	12.02
	Net income	7,246	21,355	11,188	16,056	9,195	22,025	31,407	2,158	8,062	7,812
	Depreciation	5,757	6,269	6,150	5,755	4,681	5,191	5,064	6,290	7,013	6,592
Per share, $
Per share, $	Revenue	8.68	8.80	6.95	7.35	7.50	14.51	18.04	10.55	11.23	11.01
	Earnings	1.17	3.57	1.90	2.92	1.73	3.92	5.59	0.38	1.42	1.37
	Cash flow	2.66	2.81	2.70	2.26	2.59	5.82	5.22	1.54	2.25	2.06
	Capex	(0.33)	(0.37)	(0.36)	(0.44)	(0.50)	(0.48)	(0.58)	(0.69)	(0.51)	(0.46)
	Free cash flow	2.33	2.44	2.33	1.82	2.10	5.33	4.64	0.85	1.74	1.60
	Book value	9.83	12.00	10.86	11.39	11.43	13.83	17.10	15.82	15.62	15.27
	Shares, m	6,089	5,970	5,872	5,569	5,555	5,601	5,608	5,643	5,664	5,683
Valuation, ×
Valuation, ×	P/E	26.76	9.68	22.03	12.77	21.40	15.14	9.20	82.58	18.70	18.31
	P/S	3.61	3.93	5.96	5.06	4.91	4.07	2.84	2.82	2.36	2.26
	P/B	3.19	2.88	3.81	3.26	3.22	4.27	3.00	1.88	1.70	1.63
	EV/Sales	4.07	4.37	6.52	6.10	5.57	4.16	2.97	3.81	3.05	3.08
	EV/FCF	15.19	15.85	19.43	24.64	20.40	11.63	11.91	56.83	21.49	23.28
Cash, $m
Cash, $m	Operating cash flow	16,192	16,802	15,827	12,588	14,403	32,580	29,267	8,700	12,744	11,704
	Capex	(1,999)	(2,217)	(2,136)	(2,464)	(2,765)	(2,711)	(3,236)	(3,907)	(2,909)	(2,629)
	Free cash flow	14,193	14,585	13,691	10,124	11,638	29,869	26,031	4,793	9,835	9,075
Balance, $m
Balance, $m	Working capital	7,834	10,714	18,068	(4,501)	9,147	17,022	9,121	(4,461)	7,363	5,914
	Total debt	42,086	43,491	41,740	52,150	39,836	38,436	35,829	71,888	64,351	64,795
	Net debt	24,236	23,499	22,907	42,504	27,613	7,367	13,097	59,198	43,874	51,199
	Shareholders’ equity	59,840	71,656	63,758	63,447	63,473	77,462	95,916	89,288	88,497	86,775
Returns, %
Returns, %	ROA	4.26	12.41	6.73	9.80	5.69	13.09	16.57	1.00	3.65	3.69
	ROIC	9.03	9.01	4.09	3.96	5.66	14.32	20.52	0.54	5.86	6.45
	ROE	11.56	32.42	16.48	25.20	14.43	31.19	36.19	2.29	9.03	8.87

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NVS Novartis AG	$262.0B	21.6×	20.6×	+0.78% (above 0%: growing)	−17.39% (below 0%: shrinking)	−15.53% (below 0%: shrinking)	75.19%	31.77%	Compare
AZN AstraZeneca PLC	$246.3B	23.6×	23.4×	+6.41% (above 0%: growing)	+1.90% (above 0%: growing)	−107.45% (below 0%: shrinking)	83.60%	20.57%	Compare
AMGN Amgen Inc.	$220.3B	25.6×	22.7×	+9.53% (above 0%: growing)	+65.41% (above 0%: growing)	+82.57% (above 0%: growing)	72.04%	34.95%	Compare
GILD Gilead Sciences, Inc.	$182.4B	— (loss-making)	— (loss-making)	+10.18% (above 0%: growing)	n/m	+376.81% (above 0%: growing)	79.76%	(133.21%)	Compare
PFE Pfizer Inc.	$158.6B	37.2×	12.2×	+2.60% (above 0%: growing)	n/m	+125.17% (above 0%: growing)	72.78%	20.38%
NVO Novo Nordisk A/S	$127.8B	9.4×	—	+4.47% (above 0%: growing)	−18.68% (below 0%: shrinking)	+71.57% (above 0%: growing)	78.21%	34.48%	Compare
BMY Bristol Myers Squibb Company	$121.7B	13.0×	11.2×	+5.74% (above 0%: growing)	+153.13% (above 0%: growing)	−13.16% (below 0%: shrinking)	71.28%	31.50%	Compare
SNY Sanofi	$95.9B	21.0×	—	+17.35% (above 0%: growing)	−90.76% (below 0%: shrinking)	−45.06% (below 0%: shrinking)	75.47%	17.48%	Compare
GSK GSK PLC Sponsored ADR	$93.2B	14.5×	12.4×	+5.81% (above 0%: growing)	−69.47% (below 0%: shrinking)	+54.83% (above 0%: growing)	73.05%	5.72%	Compare
Median of peers	$155.1B	21.0×	20.6×	+6.11%	−17.39%	+20.84%	75.33%	26.03%

All 21 Drug Manufacturers General stocks →

Pfizer Inc. (PFE) key facts

Concern: Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
Pfizer Inc. (PFE) is a Drug Manufacturers General company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 9, 2026, PFE traded at $28.28, a market capitalization of $158.6 billion.
Pfizer Inc. pays an annual dividend of $1.72 per share, a yield of 6.08%.
Return on equity was 8.87% and debt-to-equity 0.74.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 2.03 (grey zone) for fiscal 2025.